StockpollyBeta
Get App
Popularity #5,093
MRKR · NASDAQ · Biotechnology

Marker Therapeutics (MRKR)

Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.

$1.23
vs last close+0.02 (+2.08%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue011122011000
Cost of revenue233235342030
Gross profit−2−2−1−1−2−3−3−3−10−30
111111211213
Research & development233235342231
111111111111
General & administrative111111111111
Other expenses−2−3−3−2−3−5−3−4−2−1−30
Operating income−3−3−3−2−2−4−5−4−2−2−4−3
000000000011
Interest income000000000000
Other non-operating income0000000000−1−1
Income before tax−3−3−2−2−2−4−4−4−2−2−3−2
Income tax expense000000000000
Net income from continuing operations−3−3−2−2−2−4−4−4−2−2−3−2
Net income−3−3−2−2−2−4−4−4−2−2−3−2
EPS, basic−$0.34−$0.31−$0.27−$0.25−$0.26−$0.42−$0.40−$0.29−$0.12−$0.10−$0.16−$0.10
EPS, diluted−$0.34−$0.31−$0.27−$0.25−$0.26−$0.42−$0.40−$0.29−$0.12−$0.10−$0.16−$0.10
Weighted average shares, basic999999111417151919
Weighted average shares, diluted999999111417151919
EBITDA−3−200−2−40−4−2−2−3−2
Depreciation & amortization113200400000
EBIT−3−3−2−2−2−4−4−4−2−2−3−2